Top Markets
#1 EXOD EXOD +56.80%
#2 Cysic Cysic +14.17%
#3 Biconomy Biconomy +13.82%
#4 Fabric Protocol Fabric Protocol +7.20%
#5 Fake World Assets Fake World Assets +5.60%
#6 Collect on Fanable Collect on Fanable +4.30%
#7 Cap Cap +3.90%
#8 Dual Dual +3.58%
#9 Figure Heloc Figure Heloc +3.49%
#10 Avantis Avantis +3.32%
Coin of the day
EXOD EXOD
Настройки
Язык
Pусский
Валюта
USD
Тема
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Ранг среди акций #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Цена акции
$0.41
Последняя синхронизация: 2025-01-23
Рыночная капитализация
$1.08M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля CohBar, Inc. (CWBR)

Категория

Healthcare
Выручка компании CohBar, Inc. (CWBR)
Выручка на Jun 2023 TTM: 0.00
Согласно последним финансовым отчетам CohBar, Inc., текущая выручка компании (TTM) составляет 0.00. В 2021 году компания получила выручку 0.00 равна выручке в 2020 году, которая составила 0.00. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки CohBar, Inc. с 2012 по 2026
Выручка на конец каждого года
Год Выручка Изменить
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE